Obicetrapib and renal function: a welcome signal, but not yet a kidney story
File(s)
Published version
Author(s)
Barkas, Fotios
Ray, Kausik
Type
Journal Article
Abstract
Chronic kidney disease (CKD) and atherosclerotic cardiovascular disease (ASCVD) frequently coexist and mutually amplify risk [1]. CKD development and progression share traditional ASCVD risk factors such as ageing, hypertension, diabetes, and obesity, but also include immune-mediated and inflammatory diseases among others [1]. There are differences with inflammation promoting structural and functional alterations within the renal microvasculature, glomeruli, and tubulointerstitium, ultimately leading to progressive nephron loss [1]. Beyond these mechanisms, disturbances in lipoprotein metabolism may also contribute to cardiovascular and renal injury.
Date Issued
2026-06-01
Date Acceptance
2026-03-11
Citation
American Journal of Preventive Cardiology, 2026, 27 (1)
ISSN
2666-6677
Publisher
Elsevier
Journal / Book Title
American Journal of Preventive Cardiology
Volume
27
Issue
1
Copyright Statement
© 2026 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).
Identifier
10.1016/j.ajpc.2026.101546
Publication Status
Published
Article Number
101546
Date Publish Online
2026-03-27